The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.

Filarial parasites (e.g., Brugia malayi, Onchocerca volvulus, and Wuchereria bancrofti) are causative agents of lymphatic filariasis and onchocerciasis, which are among the most disabling of neglected tropical diseases. There is an urgent need to develop macro-filaricidal drugs, as current anti-fila...

Full description

Bibliographic Details
Main Authors: Bo Wu, Jacopo Novelli, Jeremy Foster, Romualdas Vaisvila, Leslie Conway, Jessica Ingram, Mehul Ganatra, Anita U Rao, Iqbal Hamza, Barton Slatko
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-07-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC2703803?pdf=render
_version_ 1811196196117544960
author Bo Wu
Jacopo Novelli
Jeremy Foster
Romualdas Vaisvila
Leslie Conway
Jessica Ingram
Mehul Ganatra
Anita U Rao
Iqbal Hamza
Barton Slatko
author_facet Bo Wu
Jacopo Novelli
Jeremy Foster
Romualdas Vaisvila
Leslie Conway
Jessica Ingram
Mehul Ganatra
Anita U Rao
Iqbal Hamza
Barton Slatko
author_sort Bo Wu
collection DOAJ
description Filarial parasites (e.g., Brugia malayi, Onchocerca volvulus, and Wuchereria bancrofti) are causative agents of lymphatic filariasis and onchocerciasis, which are among the most disabling of neglected tropical diseases. There is an urgent need to develop macro-filaricidal drugs, as current anti-filarial chemotherapy (e.g., diethylcarbamazine [DEC], ivermectin and albendazole) can interrupt transmission predominantly by killing microfilariae (mf) larvae, but is less effective on adult worms, which can live for decades in the human host. All medically relevant human filarial parasites appear to contain an obligate endosymbiotic bacterium, Wolbachia. This alpha-proteobacterial mutualist has been recognized as a potential target for filarial nematode life cycle intervention, as antibiotic treatments of filarial worms harboring Wolbachia result in the loss of worm fertility and viability upon antibiotic treatments both in vitro and in vivo. Human trials have confirmed this approach, although the length of treatments, high doses required and medical counter-indications for young children and pregnant women warrant the identification of additional anti-Wolbachia drugs.Genome sequence analysis indicated that enzymes involved in heme biosynthesis might constitute a potential anti-Wolbachia target set. We tested different heme biosynthetic pathway inhibitors in ex vivo B. malayi viability assays and report a specific effect of N-methyl mesoporphyrin (NMMP), which targets ferrochelatase (FC, the last step). Our phylogenetic analysis indicates evolutionarily significant divergence between Wolbachia heme genes and their human homologues. We therefore undertook the cloning, overexpression and analysis of several enzymes of this pathway alongside their human homologues, and prepared proteins for drug targeting. In vitro enzyme assays revealed a approximately 600-fold difference in drug sensitivities to succinyl acetone (SA) between Wolbachia and human 5'-aminolevulinic acid dehydratase (ALAD, the second step). Similarly, Escherichia coli hemH (FC) deficient strains transformed with human and Wolbachia FC homologues showed significantly different sensitivities to NMMP. This approach enables functional complementation in E. coli heme deficient mutants as an alternative E. coli-based method for drug screening.Our studies indicate that the heme biosynthetic genes in the Wolbachia of B. malayi (wBm) might be essential for the filarial host survival. In addition, the results suggest they are likely candidate drug targets based upon significant differences in phylogenetic distance, biochemical properties and sensitivities to heme biosynthesis inhibitors, as compared to their human homologues.
first_indexed 2024-04-12T00:54:33Z
format Article
id doaj.art-5a46d746c1184bb1ae13e0c5dd598142
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-04-12T00:54:33Z
publishDate 2009-07-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-5a46d746c1184bb1ae13e0c5dd5981422022-12-22T03:54:38ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352009-07-0137e47510.1371/journal.pntd.0000475The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.Bo WuJacopo NovelliJeremy FosterRomualdas VaisvilaLeslie ConwayJessica IngramMehul GanatraAnita U RaoIqbal HamzaBarton SlatkoFilarial parasites (e.g., Brugia malayi, Onchocerca volvulus, and Wuchereria bancrofti) are causative agents of lymphatic filariasis and onchocerciasis, which are among the most disabling of neglected tropical diseases. There is an urgent need to develop macro-filaricidal drugs, as current anti-filarial chemotherapy (e.g., diethylcarbamazine [DEC], ivermectin and albendazole) can interrupt transmission predominantly by killing microfilariae (mf) larvae, but is less effective on adult worms, which can live for decades in the human host. All medically relevant human filarial parasites appear to contain an obligate endosymbiotic bacterium, Wolbachia. This alpha-proteobacterial mutualist has been recognized as a potential target for filarial nematode life cycle intervention, as antibiotic treatments of filarial worms harboring Wolbachia result in the loss of worm fertility and viability upon antibiotic treatments both in vitro and in vivo. Human trials have confirmed this approach, although the length of treatments, high doses required and medical counter-indications for young children and pregnant women warrant the identification of additional anti-Wolbachia drugs.Genome sequence analysis indicated that enzymes involved in heme biosynthesis might constitute a potential anti-Wolbachia target set. We tested different heme biosynthetic pathway inhibitors in ex vivo B. malayi viability assays and report a specific effect of N-methyl mesoporphyrin (NMMP), which targets ferrochelatase (FC, the last step). Our phylogenetic analysis indicates evolutionarily significant divergence between Wolbachia heme genes and their human homologues. We therefore undertook the cloning, overexpression and analysis of several enzymes of this pathway alongside their human homologues, and prepared proteins for drug targeting. In vitro enzyme assays revealed a approximately 600-fold difference in drug sensitivities to succinyl acetone (SA) between Wolbachia and human 5'-aminolevulinic acid dehydratase (ALAD, the second step). Similarly, Escherichia coli hemH (FC) deficient strains transformed with human and Wolbachia FC homologues showed significantly different sensitivities to NMMP. This approach enables functional complementation in E. coli heme deficient mutants as an alternative E. coli-based method for drug screening.Our studies indicate that the heme biosynthetic genes in the Wolbachia of B. malayi (wBm) might be essential for the filarial host survival. In addition, the results suggest they are likely candidate drug targets based upon significant differences in phylogenetic distance, biochemical properties and sensitivities to heme biosynthesis inhibitors, as compared to their human homologues.http://europepmc.org/articles/PMC2703803?pdf=render
spellingShingle Bo Wu
Jacopo Novelli
Jeremy Foster
Romualdas Vaisvila
Leslie Conway
Jessica Ingram
Mehul Ganatra
Anita U Rao
Iqbal Hamza
Barton Slatko
The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
PLoS Neglected Tropical Diseases
title The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
title_full The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
title_fullStr The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
title_full_unstemmed The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
title_short The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
title_sort heme biosynthetic pathway of the obligate wolbachia endosymbiont of brugia malayi as a potential anti filarial drug target
url http://europepmc.org/articles/PMC2703803?pdf=render
work_keys_str_mv AT bowu thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jacoponovelli thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jeremyfoster thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT romualdasvaisvila thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT leslieconway thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jessicaingram thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT mehulganatra thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT anitaurao thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT iqbalhamza thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT bartonslatko thehemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT bowu hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jacoponovelli hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jeremyfoster hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT romualdasvaisvila hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT leslieconway hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT jessicaingram hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT mehulganatra hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT anitaurao hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT iqbalhamza hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget
AT bartonslatko hemebiosyntheticpathwayoftheobligatewolbachiaendosymbiontofbrugiamalayiasapotentialantifilarialdrugtarget